Eighteen distinct comparisons from 15 studies were included in the review. The total number of participants included was not clear: it was given as 290 in the text and 255 in Table 1. The authors stated that significant heterogeneity was found for most of the meta-analyses.
The authors stated that all of the studies were of a good quality. An assessment of publication bias suggested that this was only significant for one outcome (LV mass index).
Somatostatin analogue treatment was associated with a decrease in heart rate (WMD -0.47, 95% confidence interval, CI: -0.74, -0.19), LV mass (WMD -1.14, 95% CI: -2.06, -0.21), LV mass index (WMD -0.78, 95% CI: -0.97, -0.58), interventricular septum thickness (WMD -0.67, 95% CI: -0.95, -0.38) and LV posterior wall (WMD -0.50, 95% CI: -0.87, -0.14).
Somatostatin analogue treatment was associated with an increase in ratio of early to late mitral diastolic flow (WMD 0.43, 95% CI: 0.16, 0.70) and exercise duration (WMD 1.06, 95% CI: 0.43, 1.70).
No significant effect of somatostatin analogue treatment was seen for LV end-diastolic dimension, LV ejection fraction, systolic or diastolic blood-pressure, LV end-systolic diameter or fractional shortening.
The results for weighted mean change in each outcome were also reported in the review. No results of meta-regression analyses were presented.